Deka Biosciences is a biotechnology company focused on the development of novel immunotherapies to treat cancer and autoimmune diseases. The company leverages its proprietary technology platforms to create transformative treatments that aim to improve patient outcomes.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.  Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Viva BioInnovator

Echo Investment Capital

Alexandria Venture Investments

Leaps by Bayer

Lumira Ventures

Plains Ventures

Amana Investments

ATEM Capital

MPM Capital

John Mumm

Deka Biosciences, Inc

Deka Biosciences

COM:DEKABIOSCIENCES

Deka Biosciences

Analysis Not Available